I came across an interesting article published by researchers at...

I came across an interesting article published by researchers at the CSIRO (including RHY's Dr Trevor Lockett) for Pubmed in 2015. This would have been around the time they were making significant headway with their research, remembering that Rhythm Biosciences was established in 2017 for the purpose of commercialising the science that CSIRO developed over a 13 year period.

https://pubmed.ncbi.nlm.nih.gov/25793510/

Of particular interest is this statement-
"We have identified a 3 biomarker panel that has higher sensitivity and specificity for early stage (Stage I and -II) disease than the faecal occult blood test, raising the possibility for its use as a non-invasive blood diagnostic or screening test."

Early-stage specificity and sensitivity are key requirements for any population screening test.

Since the time of this article (7 years) further significant development of the Colostat test has occurred, culminating in their very successful Study 7 clinical trial of 737 patients in 2022. Here are the results of that trial -

https://newswire.iguana2.com/af5f4d73c1a54a33/rhy.asx/3A591059/RHY_Study_7_Confirms_ColoSTAT_Meets_Primary_Endpoint

The reported sensitivity of 81% means that Stage 1/2/3/4 must all be high, for example 70/80/85/90% = average 81%